Stoke Therapeutics, Inc.

NASDAQ:STOK

Biotechnology

Healthcare
$26.69 -1.12%

-$0.34 today

Market cap
$1.75B
Beta
1.19
P/E (TTM)
-11.1
EPS (TTM)
-$2.69
52W Low $11.17High $40.22

Volume 0.76M

Average 0.64M

STOK Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Stoke Therapeutics, Inc.NASDAQ: STOK

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 63.06M shares rose 6.2% year over year, ahead of the +4.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 8.0% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +6.2% holds above the trailing-twelve-month pace of +4.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
63.06M+8.0% QoQ
Last fiscal yearDec 2025
59.22M+9.6% YoY
LTMMar 2026
59.6M+4.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.2%——
1 year+9.6%——
3-year CAGR+15.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
59.22M USD
Year-over-year change
+9.6%
4-year CAGR
+12.7%

Weighted Avg Shares (Diluted) vs competitors

How STOK compares with its peers on the latest reported figures

  • STOK's LTM Mar 2026 weighted avg shares (diluted) of 59.6M shares is the 5th highest of the 7 companies compared; the peer median is 104.86M shares.
  • Its year-over-year change of +4.3% is the 4th highest of 6, against a peer median of +17.0%.
  • Over three fiscal years its annual growth of +15.0% compares with a peer median of +13.0%.
STOK Competitors Peer median
Weighted Avg Shares (Diluted) for STOK and competitors
Company Period LTM YoY 3-year CAGR
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +19.3%+28.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M -0.2%+4.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026105.94M +21.0%+13.7%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.77M +17.0%+12.2%
STOKStoke Therapeutics, Inc.LTM Mar 202659.6M +4.3%+15.0%
DSGNDesign Therapeutics, Inc.LTM Mar 202658.14M +2.6%+1.0%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
Peer median (excluding STOK) 104.86M+17.0%+13.0%

Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.41M8.78M36.56M184.42M
Cost of Revenue00000
Gross Profit012.41M8.78M36.56M184.42M
Gross Margin—100.0%100.0%100.0%100.0%
Research & Development54.17M77.84M82.23M89.13M137.92M
Selling, General & Admin31.9M38.92M41.32M48.79M67.09M
Operating Expenses86.07M116.76M123.55M137.93M205.01M
Depreciation & Amortization974K1.55M2.47M2.18M1.77M
EBITDA(84.83M)(99.52M)(102.23M)(86.8M)(5.12M)
EBITDA Margin—-802.3%-1164.4%-237.5%-2.8%
Operating Income(86.07M)(104.36M)(114.77M)(101.37M)(20.59M)
Operating Margin—-841.2%-1307.2%-277.3%-11.2%
Interest Income120K3.12M9.91M12.64M13.77M
Interest Expense00009K
Other Income / Expenses260K3.29M10.07M12.39M13.71M
Income Before Tax(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Pre-Tax Margin—-814.7%-1192.5%-243.4%-3.7%
Income Tax Expense00000
Net Income(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Net Margin—-814.7%-1192.5%-243.4%-3.7%
EPS (Basic)(2.34)(2.60)(2.38)(1.65)(0.12)
EPS (Diluted)(2.34)(2.60)(2.38)(1.65)(0.12)
Weighted Avg Shares36.74M38.9M43.99M54.01M59.22M
Weighted Avg Shares (Diluted)36.74M38.9M43.99M54.01M59.22M

Stoke Therapeutics, Inc.

NASDAQ:STOK

Intrinsic Alpha fair value

Locked

Current Price

$26.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.